Stock Market & Financial Investment News

News Breaks October 2, 2012 05:54 EDT SNY Genzyme Phase 3 study of oral Eliglustat Tartrate meets primary endpoint Genzyme, a Sanofi company, announced that ENGAGE, the first Phase 3 trial of its investigational oral therapy, eliglustat tartrate, in previously untreated patients with Gaucher disease type 1, met its primary endpoint. Patients treated with eliglustat tartrate had a statistically significant improvement in spleen size at nine months, compared with placebo. The initial safety analysis from ENGAGE suggests that eliglustat tartrate was well tolerated. There were no serious adverse events reported in the primary analysis period and no clinically meaningful differences in the related adverse events reported between the two treatment groups. Full results from the ENGAGE study are planned for presentation at the Lysosomal Disease Network WORLD meeting, Feb. 12-15, 2013, in Orlando, Fla. Top-line data from Genzyme’s second Phase 3 trial, ENCORE, are expected in early 2013. News For SNY From The Last 14 Days Check below for free stories on SNY the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 23, 2013 08:18 EDT SNY Merrimack completes enrollement in a Phase 2 study of MM-121 with Sanofi Subscribe for More Information May 21, 2013 07:44 EDT SNY Sachs Associates to host a forum Subscribe for More Information May 20, 2013 17:26 EDT SNY Regeneron, Genentech, Sanofi enter into 'Zaltrap agreement' Subscribe for More Information 11:27 EDT SNY Appeals court reverses, remands patent ruling in Sanofi suit against Mylan, Teva Subscribe for More Information May 17, 2013 08:03 EDT SNY Sanofi reports positive topline results from pivotal Phase III Jakarta study Subscribe for More Information 05:18 EDT SNY Sanofi says JAK2 inhibitor for myelofibrosis met primary endpoint Subscribe for More Information May 15, 2013 15:16 EDT SNY Sanofi systemic sclerosis treatment designated for orphan drug status Subscribe for More Information 05:39 EDT SNY Sanofi, Regeneron announce patient enrollment in two Phase 3 trials Subscribe for More Information May 13, 2013 09:44 EDT SNY Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:30 EDT SNY TechConnect to host a summit 2013 National Innovation Summit is being held in Washington, D.C. on May 12-16. Sign up for a free trial to see the rest of the stories you've been missing.